Michelle Carr, Author at BioTuesdays

Markets

Lake Street starts Profound Medical at Buy; PT $16.50

Lake Street initiated coverage of Profound Medical (NASDAQ:PROF; TSX:PRN) with a “buy” rating and $16.50 price target. The stock closed at $10.19 on July 22. Analyst Ben Haynor writes that with reimbursement of TULSA...

July 23, 2024

Developments

Cytel unveiled as alliance partner with OneMedNet

Closely-held Cytel, a global leader in clinical trial design and software, announced today its strategic partnership with OneMedNet (NASDAQ:ONMD) to enhance data-driven healthcare solutions. The partnership will...

July 22, 2024

Markets

Stifel upgrades Profound Medical to buy on CMS reimbursement; PT to $12

After market close today, Stifel upgraded Profound Medical (NASDAQ:PROF; TSX:PRN) to “buy” from “hold” and raised its price target to $12 from $9 in response to the U.S. Centers for Medicare and Medicaid Services (CMS)...

July 15, 2024

Markets

EF Hutton starts Citius Pharmaceuticals at buy; PT $6

EF Hutton launched coverage of Citius Pharmaceuticals (NASDAQ:CTXR) a “buy” rating and $6 target price. The stock closed at $0.7340 on July 12. Citius is a pharmaceutical/biotechnology company with two late-stage assets...

July 15, 2024

Markets

Raymond James upgrades Alpha Cognition to outperform; PT to $2

Raymond James upgraded Alpha Cognition (CSE:ACOG) to “outperform” from “market perform” and raised its price target to C$2 from C$1 with the company’s PDUFA date less than 2 weeks away (July 27th). The stock closed at...

July 15, 2024

Developments

Remembering Elias Vamvakas, a friend and mentor

For the first time since we began publishing in 2009, the BioTuesdays family is lost for words, almost. With devastating sadness, we learned today of Elias Vamvakas’ passing. A pioneering entrepreneur in the Canadian...

July 11, 2024

Markets

Rodman & Renshaw starts BioRestorative Therapies at buy; PT $15

Rodman & Renshaw launched coverage of BioRestorative Therapies (NASDAQ:BRTX) with a “buy” rating and $15 target price. The stock closed at $2.02 on June 26. BioRestorative develops therapeutic products using cell...

June 27, 2024

Developments

BioRestorative Therapies gains media attention for key regenerative medicine programs

Benzinga editor, Tony Noto, interviewed Lance Alstodt, BioRestorative’s (NASDAQ:BRTX) Chief Executive Officer, about the company’s two core clinical development programs (BRTX-100 targeting disc/spine disease and...

June 20, 2024

Developments

Inogen shares published study results demonstrating association of portable oxygen therapy with increased survival and cost-effectiveness

Inogen (NASDAQ:INGN) reported that the peer-reviewed journal, Pulmonary Therapy, has published a study demonstrating the association of portable oxygen concentrators with decreased mortality and increased cost...

June 5, 2024

Developments

Profound Medical highlights TULSA’s potential to become a mainstream treatment modality across the entire prostate disease spectrum

Profound Medical (NASDAQ:PROF; TSX:PRN) announced that a total of 25 clinical presentations highlighting TULSA procedure’s ability to effectively, safely and efficiently treat an unrivaled variety of prostate cancer...

May 6, 2024

Author - Michelle Carr

Lake Street starts Profound Medical at Buy; PT $16.50

Cytel unveiled as alliance partner with OneMedNet

Stifel upgrades Profound Medical to buy on CMS reimbursement; PT to $12

EF Hutton starts Citius Pharmaceuticals at buy; PT $6

Raymond James upgrades Alpha Cognition to outperform; PT to $2

Remembering Elias Vamvakas, a friend and mentor

Rodman & Renshaw starts BioRestorative Therapies at buy; PT $15

BioRestorative Therapies gains media attention for key regenerative medicine programs

Inogen shares published study results demonstrating association of portable oxygen therapy with increased survival and cost-effectiveness

Profound Medical highlights TULSA’s potential to become a mainstream treatment modality across the entire prostate disease spectrum

General

More